| 0 (0%) | 10-15 12:16 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 73.52 | 1-year : | 85.87 |
| Resists | First : | 62.95 | Second : | 73.52 |
| Pivot price | 57.7  |
|||
| Supports | First : | 50.07 | Second : | 42.11 |
| MAs | MA(5) : | 56.24  |
MA(20) : | 57.91 |
| MA(100) : | 30.87 |
MA(250) : | 20.51 |
|
| MACD | MACD : | 3.5 |
Signal : | 4.7 |
| %K %D | K(14,3) : | 41.5 |
D(3) : | 33.8 |
| RSI | RSI(14): 59 |
|||
| 52-week | High : | 62.95 | Low : | 0.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NKTR ] has closed above bottom band by 36.8%. Bollinger Bands are 46.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 58.45 - 58.78 | 58.78 - 59.04 |
| Low: | 54.52 - 54.97 | 54.97 - 55.33 |
| Close: | 56.41 - 57.09 | 57.09 - 57.64 |
Wed, 15 Oct 2025
Why NKTR stock attracts high net worth investors - Watch List & Trade Opportunity Analysis - newser.com
Wed, 15 Oct 2025
Using flow based indicators on NKTR - Weekly Profit Analysis & Low Risk Profit Maximizing Plans - newser.com
Mon, 13 Oct 2025
How Investors Are Reacting To Nektar Therapeutics (NKTR) Securing FDA Fast Track For Eczema Drug Candidate - simplywall.st
Mon, 13 Oct 2025
FDA Fast Track for Eczema Therapy Could Be a Game Changer for Nektar Therapeutics (NKTR) - Yahoo Finance
Mon, 13 Oct 2025
Nektar Therapeutics (NKTR): Assessing Valuation After a Strong Multi-Month Share Price Rally - Yahoo Finance
Tue, 09 Sep 2025
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 19 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 48.4 (%) |
| Shares Short | 1,970 (K) |
| Shares Short P.Month | 1,120 (K) |
| EPS | -8.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.95 |
| Profit Margin | -163.2 % |
| Operating Margin | -320.3 % |
| Return on Assets (ttm) | -31.6 % |
| Return on Equity (ttm) | -440.8 % |
| Qtrly Rev. Growth | -52.5 % |
| Gross Profit (p.s.) | 3.28 |
| Sales Per Share | 3.93 |
| EBITDA (p.s.) | -7.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -185 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -6.57 |
| PEG Ratio | 0 |
| Price to Book value | -29.26 |
| Price to Sales | 14.4 |
| Price to Cash Flow | -5.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|